ABL TherapyEdge Dr Chalom B Sayada, MD, PhD Administrateur dlgu - - PowerPoint PPT Presentation

▶
abl therapyedge
SMART_READER_LITE
LIVE PREVIEW

ABL TherapyEdge Dr Chalom B Sayada, MD, PhD Administrateur dlgu - - PowerPoint PPT Presentation

Nov 30, 2023 370 likes •659 views

ABL TherapyEdge Dr Chalom B Sayada, MD, PhD Administrateur dlgu ABL SA IT and Bio Informatics products for optimal personalized healthcare in chronic diseases AREVIR Meeting Cologne, GERMANY May 5th, 2011 Mission &

slide-1
SLIDE 1

ABL – TherapyEdge

Dr Chalom B Sayada, MD, PhD Administrateur délégué ABL SA

AREVIR Meeting Cologne, GERMANY May 5th, 2011

IT and Bio‐Informatics products for

  • ptimal personalized

healthcare in chronic diseases

slide-2
SLIDE 2

Mission & Current status

  • ABL is

focused

  • n the growing need for informatics‐driven

physician‐centric reporting for complex test results (such as in molecular testing where Siemens is highly involved), to enhance test reporting in all areas of testing, including oncology, genetics, and infectious disease.

  • More than

25 modules and applications

  • Active R&D programs in several

fields

  • Current

customer base:

  • Europe, Africa, Asia and recently

USA

  • 150 clinics

(Research, Routine)

  • ~150’000 patients with

medical history

  • ~10’000s of visits

per day

  • >100’000 lab

data integrated per day, including HIV/Hepatitis genotyping

slide-3
SLIDE 3

ABL-TherapyEdge group

slide-4
SLIDE 4

International & National Guidelines EACS, DHHS, EASL, AASLD Knowledge & Standardised Databases (ICD10, ATC), LOINC, EMEA, FDA Laboratory Module Clinical Module

LIS HIS

Online services & Expert Algorithms

Optimal Patient Care Personalised Medicine

The TherapyEdge platform

slide-5
SLIDE 5

“Turn key” solution to install and

  • pen new site

Automated installation & upgrades

Installation time : 40 minutes

Easy configuration over any network

Automated/Regular updates

Operating system

Releases (new functionalities)

Content / Decision support : Drug/Drug interactions, Resistance algorithms, TherapyEval…

4 Applications & third party online services:

TherapyEdge

ViroScore

DeepChek

FibroMeters

TherapyEdge Box

slide-6
SLIDE 6

HIS LIS

TE Expert & Decision support tools

TherapyEval VS UDS‐ HIV/HBV/HCV (Consensus) VS UDS‐ HIV/HBV/HCV (Amplicons)

Third‐party services

VS‐HIV/HBV/HCV VircoType FibroMeters SeqHepB

Data import

Manual entry Advanced & central patient data repository

The solutions –

Integration

“All-in-one” patient data repository

slide-7
SLIDE 7
  • TherapyEdge

– EHR system – Clinical & Biological database – Multiple knowledge‐bases

  • FibroMeters

– Non invasive liver fibrosis analysis

  • ViroScore

– (Sanger sequencing) Data management

  • DeepChek

– (UltraDeepSequencing) Data Management

slide-8
SLIDE 8

The solutions – TherapyEdge

Key features

slide-9
SLIDE 9

The solutions – TherapyEdge

From simple to complexe IT structures (1) : Europe and South Africa

slide-10
SLIDE 10

The solutions – TherapyEdge

From simple to complexe IT structures (2): Botswana PPP (20’000 HIV patients)

slide-11
SLIDE 11

The solutions – TherapyEdge Right To Care (NGO in South Africa): HIV PATIENT RETENTION WITHIN SIX

MONTHS OF ARV INITIATION at the Themba Lehtu Clinic (Johanesbourg, South Africa)

TE hybrid TE Real Time No Clinic charge

Quarterly Initiation Period Ref: Evans D., Nagar S., et al., unpublished

slide-12
SLIDE 12

Patient clinical data Knowledge database

This patient is

  • n ATZ/R + 3TC + FTC.

We can directly see the possible interaction between ATZ and TDF and also between TDF / FTC and trimethoprim (the patient is also

  • n Bactrim).

TherapyEval gives some recommendation

  • n the dosage of each

ARV based

  • n

the weight

  • f

the patient. This patient is

  • n ATZ/R + 3TC + FTC.

We can directly see the possible interaction between ATZ and TDF and also between TDF / FTC and trimethoprim (the patient is also

  • n Bactrim).

TherapyEval gives some recommendation

  • n the dosage of each

ARV based

  • n

the weight

  • f

the patient.

The solutions – TherapyEdge

TherapyEval module

slide-13
SLIDE 13

The solutions – ViroScore SUITE

Key features

slide-14
SLIDE 14

The solutions – ViroScore SUITE

Tools & Reports

slide-15
SLIDE 15

Patient summary graph TherapyEval

The solutions – ViroScore SUITE

Integration with TherapyEdge

slide-16
SLIDE 16

The solutions – ViroScore SUITE

VircoType reports

slide-17
SLIDE 17

ViroScore

Real‐time

Sequence

The solutions – ViroScore SUITE

VircoType integration

slide-18
SLIDE 18

IrsiCaixa & Lluita contra la SIDA Fdns, Spain Lidia Ruiz, José Ramon Santos & Bonaventura Clotet Hospital San Cecilio, Granada, Spain Federico García Hospital 12 de Octubre, Madrid, Spain Rafael Delgado Mútua de Terrassa, Terrassa, Spain David Dalmau, Daniel Irigoyen Max Planck Institute Informatik, Germany Alexander Thielen Roche Diagnostics , S.L., Spain Artur Palet, Miguel Álvarez‐Tejado Therapy Edge, ABL S.A., Luxembourg Chalom Sayada, Dimitri Gonzalez Spanish Ministry

  • f

Science and Innovation – Centro de Desarrollo Tecnológico Industrial (CDTI)

Acknowledgements

PRIUS project status Towards a GS 454 Junior/DeepChek-HIV clinical genotyping complete solution

slide-19
SLIDE 19

Design: Observational, multicenter, retrospective cohort study with ~250 HIV patients. Objectives: Estabish a fully integrated database (clinical, biological, UDS), use UDS to increase cost effectiveness

  • f

Drug resistance testing Participant centers

Laboratorio de Retrovirología irsiCaixa, Badalona, (centro coordinador del estudio), Roger Paredes, Bonaventura Clotet Hospital 12 de Octubre, Madrid, Rafael Delgado Mútua de Terrassa, Terrassa, David Dalmau Hospital Universitario San Cecilio, Granada, Federico Garcia Roche Diagnostics, S.L., España, Artur Palet Therapy Edge, ABL, Luxembourg, Ronan Boulme

UDS HIV Project – Prius

Design & groups

slide-20
SLIDE 20

DeepChek report (amplicon by amplicon) UDS/DeepChek data DeepChek settings :

‐ Type of VS‐UDS analysis ‐ Template ‐ Cutoff % prevalence ‐ Specific profiles ‐ Resistance analysis

  • ptions

‐ … Amplicon Prevalenc e Subtype Interpretations 1 12% B

AZT LPV DRV STAN R (100%) I (66%) S RIS R (75%) I (100%) S

Detailed interpretation Detailed individual report

DeepChek report (major population)

Type of report (configurable)

The solutions – DeepChek

Overview

slide-21
SLIDE 21

Clinical Data LAB Tests

  • Primers Definition
  • Titanium Plates
  • Sequencing Protocol

ANALYSIS PHASE PROCESSING PHASE

  • Processing Protocol
  • Automated Procedure
  • Specific Routines
  • Software Package

AVA-Software INTERPRETATION PHASE

  • Clinical Station
  • Software Product
  • Different Levels of analysis
  • RUO vs IVD ?
  • Monitoring Patients
  • Aids Decision Making

Population Analysis (15% / 10% / 5% / 1% …) Clonal Analysis

Basic Analysis Expert Analysis

The solutions – Roche 454 / DeepChek- HIV/HEP

Toward a complete Clinical Genotyping Diagnostic solution

slide-22
SLIDE 22

UDS HIV Project – Prius

Preliminary results

slide-23
SLIDE 23

BioLiveScale (BLS) Fibrometer fully integrated Manage Hepatitis within TherapyEdge ‐Viral hepatitis (A, B, C, D, E, F,G) ‐Alcoholic ‐Drug‐induced… TE viral hepatitis TE viral hepatitis Fibrosis scoring : Fibrometers Fibrosis scoring : Fibrometers Guidance & alerts dedicated to Hepatitis management. TherapyEval Hepatitis TherapyEval Hepatitis Evivar SeqHepB fully integrated Drug resistance : SeqHepB Drug resistance : SeqHepB ViroScore viral Hepatitis B & C ViroScore viral Hepatitis B & C

The solutions – Hepatitis modules

Overview

slide-24
SLIDE 24

Design: Observational, multicenter, retrospective cohort study. Participant centers

Vall d’Hebron Institue Recerca (VHIR), Pr. Estaban CiberEHD Roche Diagnostics, S.L., España, Artur Palet TherapyEdge, ABL Spain, Barcelona, Chalom Sayada Hosp.Univ.Vall d’Hebron (HUVH) - Barcelona, Juan Igniacio Estaban & Rafael Esteban

  • Hosp. Clínic. Barcelona, Xavier Forns – Barcelona
  • Hosp. Carlos III. – Madrid, Javier García-Samaniego

IPB López Neyra. - Granada, Jordi Gómez

  • Hosp. de la Princesa. - Madrid, Ricardo Moreno

Hosp.Univ. De Valme. - Sevilla, Manuel Romero

  • Hosp. San Cecilio. – Granada, Javier Salmeron

UDS/DeepChek Hepatitis Project – CIBEREHD/Roche/ABL

(Spanish Hepatology Clinical and Virological network)

slide-25
SLIDE 25

25 FibroMeters presentation, May 11th 2011

UDS Hepatitis Project – Global organization

Carlos III Valme …

Local capturing & recruitment Local capturing & recruitment Local capturing & recruitment

Vall d’Hebron

Local capturing & recruitment + inclusion (validation)

Data transfer 454-Junior + DeepChek-Hep Web access

slide-26
SLIDE 26

Virtual Biopsy (replace Liver biopsy)

Adapted to the type of Hepatitis

Viral Hepatitis (FibroMeter V)

2G (with hyaluronic acid)

3G (without hyaluronic acid)

Alcoholic Hepatitis (FibroMeter A)

Steatosis Hepatitis (FibroMeter S)

Cirrhosis

Co‐infections (HIV/Hepatitis)

Several indicators available

Score + Metavir stage

Inflammation scoring – Inflameter

Area of fibrosis

Well validated technology

Compared with competitors (FibroTest…)

Approved by the French High Health Authority

Fully integrated in the TherapyEdge platform

The solutions – Hepatitis modules

The FibroMeter non invasive tests (liver fibrosis)

slide-27
SLIDE 27

Hepatologist FibroMeter server central lab…

Mail, fax… Processing FibroMeter report sent back (mail, fax…)

The solutions – Hepatitis modules

FibroMeter offline ordering & reporting

slide-28
SLIDE 28

Thank You !

Value proposition: Explore collaborations with Clinicians, Virologists and Bioinformaticians, for Research and Routine projects, for Commercial and Non‐for‐profit activities, in the Western and Developing world, in Virology and

  • ther chronic diseases